Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 1.00 |
| ▸ | BCHE | P06276 | 11/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.80 |
| ▸ | PDE5A | O76074 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | APP | P05067 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | DRD4 | P21917 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | MAOB | P27338 | 1/20 | 0.80 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4202204 | 0.99 | ACHE (0.98) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL4213274 | 0.91 | ACHE (0.83) | ACHEBCHEFAAHABCC4CACNA1F | |
| Hydrochloric Acid SCHEMBL4200734 | 0.90 | ACHE (0.81) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL4201141 | 0.89 | ACHE (1.00) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL13284566 | 0.89 | ACHE (1.00) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL12375152 | 0.89 | ACHE (1.00) | ACHEBCHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL12043710 | 0.89 | BCHE (1.00) | ACHEBCHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL8265876 | 0.89 | BCHE (1.00) | ACHEBCHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3516 | 0.89 | BCHE (1.00) | ACHEBCHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL2149 | 0.89 | BCHE (1.00) | ACHEBCHEFAAHABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2140868-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy | Eisai R&D Management Co., Ltd. (JP) | 2010-01-06 | — | — | EP | claimed |
| EP-2138177-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2009-12-30 | — | — | EP | claimed |
| EP-2133078-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2009-12-16 | — | — | EP | claimed |
| EP-2130538-A1 | Use of a cholinesterase inhibitor for the delaying the onset of Alzheimer's disease | Eisai R&D Management Co., Ltd. (JP) | 2009-12-09 | — | — | EP | claimed |
| US-20090137629-A1 | Sigma receptor binding agent containing indanone derivative | IIMURA YOICHI | 2009-05-28 | — | — | US | claimed |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2008-12-18 | — | — | US | claimed |
| EP-1729761-A4 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | EISAI CO LTD (JP) | 2008-09-03 | — | — | EP | claimed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| JP-2001515480-A | — | — | 2001-09-18 | — | — | JP | claimed |
| WO-2001066114-A1 | NOVEL METHODS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2001-09-13 | — | — | WO | claimed |
| EP-0742207-B1 | 2-(Indan-1-one-2-yl-alkyl)-1-phenylalkyl-piperidines and processes for their preparation | EISAI CO LTD (JP) | 2001-08-29 | — | — | EP | claimed |
| EP-0971713-A1 | USE OF CHOLINESTERASE INHIBITORS TO TREAT DISORDERS OF ATTENTION | Eisai Co., Ltd. (JP) | 2000-01-19 | — | — | EP | claimed |
| WO-1998039000-A1 | USE OF CHOLINESTERASE INHIBITORS TO TREAT DISORDERS OF ATTENTION | EISAI CO., LTD. (JP) | 1998-09-11 | — | — | WO | claimed |
| EP-0296560-B1 | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease | EISAI CO LTD (JP) | 1996-02-28 | — | — | EP | claimed |
| EP-0673927-A1 | 4-[2-indanyl-1-one]alkylpiperidines as anticholinergic agents | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | claimed |
| EP-0296560-A2 | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease | Eisai Co., Ltd. (JP) | 1988-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | ACHE 1/4885BCHE 2/4885FAAH 1075/4885 |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885BCHE 137/4885FAAH 861/4885 |
| US-20090137629-A1 | Sigma receptor binding agent containing indanone derivative | SIGMAR1, TMEM97, OPRK1 | ACHE 608/4885BCHE 1667/4885FAAH 2437/4885 |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | NOTCH3, NOTCH2, NOTCH4 | ACHE 156/4885BCHE 38/4885FAAH 1617/4885 |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885BCHE 137/4885FAAH 861/4885 |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | PSEN1, BACE1, PSENEN | ACHE 26/4885BCHE 137/4885FAAH 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.